Milestone Events and Payments. Upon the first achievement by Astellas (or its Related Party) of any milestone event set forth in any table in Section 4.2.1, 4.2.2, 4.2.3 or 4.2.4 (each, a “Milestone Event”), Astellas shall notify Ambit thereof in writing not later than ten (10) Business Days after such Milestone Event is achieved, and Astellas shall pay to Ambit the applicable non-refundable, non-creditable, one-time milestone payment within […***…] following the achievement of the Milestone Event. For the avoidance of doubt, following the achievement of any Milestone Event with respect to a particular Indication, if a second Product achieves the same Milestone Event for the same Indication, no additional milestone payment shall be payable with respect to such Milestone Event. Milestone payments for the achievement of Milestone Events with respect to the EU shall be payable following the achievement of the applicable Milestone Event in any Major EU Country or, in the case of a centralized EU filing or approval, with respect to the EMEA. ***Confidential Treatment Requested CONFIDENTIAL
Milestone Events and Payments. Grünenthal shall pay to MSB the amount set forth in the tables below upon the occurrence of the corresponding event in accordance with Section 9.1.2 of the Agreement.
Milestone Events and Payments. Novartis will pay the milestone payments set forth below for the first SMA Program Product and the first HD Program Product to achieve such Development Milestone Event (each, a “Development Milestone Payment”). After receipt of a Development Milestone Event Notice, Voyager shall submit an Invoice to Novartis with respect to the corresponding Development Milestone Payment. If for any reason a Development Milestone Event (c) below does not occur prior to the occurrence of Development Milestone Event (d) below, then Development Milestone Event (c) will be deemed to occur concurrently with the occurrence of Development Milestone Event (d), and the Development Milestone Payments associated with both Development Milestone Events will be paid following the achievement of Development Milestone Event (d). Development Milestone EventDevelopment Milestone Payment SMA ProgramHD Program
Milestone Events and Payments. On a Development Candidate-by-Development Candidate basis, JPI will pay Arcturus the following non-refundable, non-creditable milestone payments, upon first achievement of the specified milestone by the first two Licensed Products for each of (i) HBV, (ii) […***…] and (iii) each of the Respiratory Disease Viruses-based Research Program added upon exercise of an Option pursuant to Section 4.2 to achieve that milestone, regardless of how many Licensed Products achieve such milestone. Each milestone payment may be paid no more than twice for each of (i) HBV, (ii) […***…] and (iii) each of the Respiratory Disease Viruses-based Research Program added upon exercise of an Option pursuant to Section 4.2, regardless of how many Licensed Products meet such milestone. If development or other efforts to obtain ***Confidential Treatment Requested Regulatory Approval of a Licensed Product are discontinued after JPI has paid the milestone payment(s) for achievement of one or more milestones (a “Dropped Licensed Product”), and JPI develops a Licensed Product containing a different Development Candidate (a “Replacement Licensed Product”) that is payable as a replacement for the Dropped Licensed Product, the milestone payment that would be payable for the achievement by such Replacement Licensed Product of any milestone previously achieved by the Dropped Licensed Product for which JPI paid a milestone payment to Arcturus would not be payable, but the milestone payment that would be payable for the achievement by such Replacement Licensed Product of any milestone that was not achieved by the Dropped Licensed Product would be payable at […***…]*% of the relevant amount set forth below. Milestone Number Milestone Event Milestone Payment 1 […***…] $[…***…] 2 […***…] $[…***…] 3 […***…] $[…***…] 4 […***…] $[…***…] 5 […***…] $[…***…] 6a […***…] $[…***…] 6b […***…] $[…***…] 6c […***…] $[…***…] Total Milestones for each of the first two Licensed Products in HBV and, if the Option is exercised pursuant to Section 4.2, Milestones for each of the first two Licensed Products in each of the applicable Option Disease Areas as provided in Section 5.3 $56,500,000 ***Confidential Treatment Requested
Milestone Events and Payments. No later than [***] after the later of (a) achievement of the regulatory milestone event for the Licensed Product set forth below and (b) receipt from BioCryst of the Tax Documents, Torii will pay to BioCryst the corresponding regulatory milestone payment as set forth below (the regulatory milestone event set forth in Table 8.2.1, the “Milestone Event,” and the regulatory milestone payment set forth in Table 8.2.1, the “Milestone Payment”). Notwithstanding anything to the contrary in this Section 8.2.1 (Milestone Events and Payments), if (i) the Adjusted XXX Xxxxx upon receipt of Regulatory Approval and Reimbursement Approval from the MHLW for the Licensed Product in HAE-P in the Territory is less than [***] or (ii) either of Regulatory Approval or Reimbursement Approval for the Licensed Product in HAE-P in the Territory has not been obtained by December 31, 2021, then no Milestone Payment will be due to BioCryst upon the achievement of such Milestone Events. Table 8.2.1 – REGULATORY MILESTONES
Milestone Events and Payments. Notwithstanding anything to the contrary in this Agreement, this Section 5.4.2 shall apply only if Novartis exercises the
Milestone Events and Payments. Xxxxx shall make the non-refundable and non-creditable payments to Verve described in this Section 10.3 (collectively, the “Milestone Payments”) after the achievement of the corresponding events set forth in this Section 10.3 with respect to Royalty Products (collectively, the “Milestone Events”).
Milestone Events and Payments. The Definitive Agreement will contain the following provisions with respect to milestone events and payments, with total milestone payments capped at US$50 MILLION:
Milestone Events and Payments. Notwithstanding anything to the contrary in this Agreement, this Section 5.4.2 shall apply only if Novartis exercises the corresponding Option. Novartis will pay the milestones payments set forth below for the first Licensed Product for each Licensed Target to achieve such Development Milestone Event (each, a “Development Milestone Payment”). After receipt of a Development Milestone Event Notice, Voyager shall submit an invoice to Novartis substantially in the form of Exhibit A with respect to the corresponding Development Milestone Payment. If for any reason a Development Milestone Event (a) below does not occur prior to the occurrence of Development Milestone Event (b) below, then Development Milestone Event (a) will be deemed to occur concurrently with the occurrence of Development Milestone Event (b), and the Development Milestone Payments associated with both Development Milestone Events will be paid following the achievement of Development Milestone Event (b). Development Milestone EventDevelopment Milestone Payment (per Licensed Target)
Milestone Events and Payments. Milestone Number Milestone Event Payment Amount 1 Completion of technical transfer by Advaxis to Licensee of all Licensed Technology which enables the manufacture of the Product using a drying method, provided that Licensee has provided prior written request for such technical transfer. Such transfer shall occur as soon as reasonably practicable following the Effective Date, however, the milestone payment shall not be due until the later of (i) the completion of the transfer and (ii) two years and six months after the Effective Date. [c.i.]
